



Notice Regarding Finalization of the FY2025 Grant Amount for AMED Public Offering Project "Development of Infrastructure Technology for the Industrialization of Regenerative Medicine and Gene Therapy"

June 11, 2026

REPROCELL Inc. (the "Company") hereby announces that the grant amount for the following research and development project, which was previously selected under the FY2025 Development of Infrastructure Technology for the Industrialization of Regenerative Medicine and Gene Therapy (Project to Promote the Industrialization of Regenerative Medicine, Cell Therapy, and Gene Therapy), a public offering project conducted by the Japan Agency for Medical Research and Development (AMED), has been finalized as described below.

Development of a Novel GPC-1 CAR-T Therapy for GPC-1 Positive Recurrent and Refractory Solid Tumors

(As disclosed in the "Notice Concerning Selection for AMED's Public Offering Project 'Development of Infrastructure Technology for the Industrialization of Regenerative Medicine and Gene Therapy' (Project Title: Development of a Novel GPC-1 CAR-T Therapy for GPC-1 Positive Recurrent and Refractory Solid Tumors)" dated December 10, 2024.)

Finalized grant amount payable to the Company: 89,692 thousand yen

The finalized grant amount will be recognized as subsidy income under non-operating income in the financial results for the first quarter of the fiscal year ending March 31, 2027. This will have no impact on the consolidated financial forecast for the fiscal year ending March 31, 2027.